John Maraganore's RNAi biotech City Ther­a­peu­tics de­buts with $135M Se­ries A

City Ther­a­peu­tics has launched with $135 mil­lion and Al­ny­lam’s for­mer CEO lead­ing the charge as it de­vel­ops a pipeline of next-gen­er­a­tion RNAi ther­a­pies that could …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER